Contrary to early reports of lessening titers of anti-SARS-CoV-2 antibodies, the proteins continue for approximately 6 months so far, versus a background of building proof for strong T-cell reactions. Medscape Medical News
Read More
Contrary to early reports of lessening titers of anti-SARS-CoV-2 antibodies, the proteins continue for approximately 6 months so far, versus a background of building proof for strong T-cell reactions. Medscape Medical News
Read More